PL335652A1 - Hydrogenated crystalline sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylprolidin-3-ylidenomethyl)-1h-indolo-2-carboxylic acid - Google Patents

Hydrogenated crystalline sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylprolidin-3-ylidenomethyl)-1h-indolo-2-carboxylic acid

Info

Publication number
PL335652A1
PL335652A1 PL98335652A PL33565298A PL335652A1 PL 335652 A1 PL335652 A1 PL 335652A1 PL 98335652 A PL98335652 A PL 98335652A PL 33565298 A PL33565298 A PL 33565298A PL 335652 A1 PL335652 A1 PL 335652A1
Authority
PL
Poland
Prior art keywords
phenylprolidin
ylidenomethyl
indolo
dichloro
oxo
Prior art date
Application number
PL98335652A
Other languages
English (en)
Inventor
Zadeo Cimarosti
Paolo Maragni
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of PL335652A1 publication Critical patent/PL335652A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL98335652A 1997-03-05 1998-03-03 Hydrogenated crystalline sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylprolidin-3-ylidenomethyl)-1h-indolo-2-carboxylic acid PL335652A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9704498.6A GB9704498D0 (en) 1997-03-05 1997-03-05 Chemical compound

Publications (1)

Publication Number Publication Date
PL335652A1 true PL335652A1 (en) 2000-05-08

Family

ID=10808697

Family Applications (1)

Application Number Title Priority Date Filing Date
PL98335652A PL335652A1 (en) 1997-03-05 1998-03-03 Hydrogenated crystalline sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylprolidin-3-ylidenomethyl)-1h-indolo-2-carboxylic acid

Country Status (29)

Country Link
EP (1) EP0966463A1 (id)
JP (1) JP2001513796A (id)
KR (1) KR20000075907A (id)
CN (1) CN1249750A (id)
AP (1) AP9901637A0 (id)
AR (1) AR011178A1 (id)
AU (1) AU6825198A (id)
BG (1) BG103779A (id)
BR (1) BR9808305A (id)
CA (1) CA2282851A1 (id)
CO (1) CO4940415A1 (id)
EA (1) EA199900710A1 (id)
EE (1) EE9900387A (id)
GB (1) GB9704498D0 (id)
HR (1) HRP980114A2 (id)
HU (1) HUP0002109A2 (id)
ID (1) ID24207A (id)
IL (1) IL131489A0 (id)
IS (1) IS5166A (id)
NO (1) NO994303L (id)
NZ (1) NZ337315A (id)
OA (1) OA11154A (id)
PE (1) PE51399A1 (id)
PL (1) PL335652A1 (id)
SK (1) SK119699A3 (id)
TR (1) TR199902117T2 (id)
WO (1) WO1998039327A1 (id)
YU (1) YU43499A (id)
ZA (1) ZA981791B (id)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704499D0 (en) * 1997-03-05 1997-04-23 Glaxo Wellcome Spa Method of manufacture
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CN110996948A (zh) 2017-06-12 2020-04-10 格莱泰施有限责任公司 用nmda拮抗剂和d2/5ht2a或选择性5ht2a拮抗剂治疗抑郁症

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds

Also Published As

Publication number Publication date
GB9704498D0 (en) 1997-04-23
WO1998039327A1 (en) 1998-09-11
BR9808305A (pt) 2000-05-16
EP0966463A1 (en) 1999-12-29
ID24207A (id) 2000-07-13
EE9900387A (et) 2000-04-17
CO4940415A1 (es) 2000-07-24
PE51399A1 (es) 1999-06-07
IS5166A (is) 1999-08-27
IL131489A0 (en) 2001-01-28
AU6825198A (en) 1998-09-22
SK119699A3 (en) 2000-05-16
KR20000075907A (ko) 2000-12-26
ZA981791B (en) 1999-09-03
TR199902117T2 (xx) 2000-03-21
HRP980114A2 (en) 1998-12-31
NO994303L (no) 1999-11-03
JP2001513796A (ja) 2001-09-04
OA11154A (en) 2003-04-16
CN1249750A (zh) 2000-04-05
NO994303D0 (no) 1999-09-03
AP9901637A0 (en) 1999-09-30
YU43499A (sh) 2000-12-28
NZ337315A (en) 2001-02-23
EA199900710A1 (ru) 2000-04-24
AR011178A1 (es) 2000-08-02
BG103779A (en) 2000-06-30
CA2282851A1 (en) 1998-09-11
HUP0002109A2 (hu) 2001-04-28

Similar Documents

Publication Publication Date Title
EG24224A (en) Omeprazole sodium salt
PL345205A1 (en) New 3-aryl-2-hydroxypropionic acid derivative (i)
IL139470A0 (en) Oxyiminoalkanoic acid derivatives
HUP0003881A3 (en) Amidocarboxylic acid derivatives
IL144107A0 (en) Potassium salt of (s)-omeprazole
HU9801044D0 (en) Sulfonyl-amino-carboxylic acid derivatives
PL345794A1 (en) Aminomethylcarboxylic acid derivatives
PL339659A1 (en) Crystalline antimycotic polymorph
AP2001002078A0 (en) Crystalline forms of et02c-ch2(r)cgl-aze-pab-oh
ZA957188B (en) Use of 5-substituted pyridine- and hexahydroquinoline-3-carboxylic acid derivatives
AU1917899A (en) Crystalline sodium phenytoin monohydrate
MXPA00012647A (es) Derivados n-sustituidos de acido 5-oxiiminobarbiturico.
HUP9801924A3 (en) Combination containing sodium/hydrogen exchange inhibitors
PL340461A1 (en) Derivatives of isothiazocarboxylic acid
AP9901457A0 (en) Novel dihydroxyexanoic acid derivatives
AU2674497A (en) Crystallization of sodium carbonates using alcohols
AU1817700A (en) 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
IL131489A0 (en) Crystalline hydrated sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylphyrrolidin-3-ylidene methyl)-1h-indole-2-carboxylic acid
GB9705031D0 (en) 2-substituted benzoyl-cycloalkyl-1-carboxylic acid derivatives
AU5767098A (en) Stabilized sodium carbonate peroxyhydrate
ZA200007084B (en) Novel salts of N-tert-butylhydroxylamine.
HK1022899A (en) Crystalline hydrated sodium salt of (e)-4, 6-dichloro-3-(2-oxo-1-phenylpyrrolidin-3-ylidene methyl)-1h-indole-2-carboxylic acid
AUPP355498A0 (en) Salt poultice
AU1719700A (en) Selective inhibitors of mmp-12
SI0991641T1 (en) Crystalline form of omeprazole sodium salt